Cerebral-spinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a study that analyzed cryopreserved CSF samples from 160 individuals.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Detailed Program Agenda Released for 2026 Scientific Sessions BOULDER, Colo., June 10, 2026 /PRNewswire/ — The American Society for Preventive Cardiology (ASPC) announces its 2026 Congress on Cardiovascular Disease Prevention, July 31 – August 2, […]
The DBJ caught up with CEO Mark Frank to learn more. Click here to view original postClick Here to Publish/Feature Your Company or Product News with Biotech Networks
Funding has declined year-over-year for the sector since it peaked in 2021. Click here to view original post
Copyright © 2026 Biotech Networks
